Kwality Pharma is in the business of manufacturing & trading in Pharmaceuticals & allied productsBusiness Overview: KPL is in an ANVISA and EU GMP certified manufacturer of all pharma products including complex molecules across all dosage forms including niche Biologics. It has a portfolio of 3000+ formulations across 25+ therapeutic...
The company has announced key changes to its Board of Directors. Mr. Vinod Kumar Sharma has been appointed as an Additional (Non-Executive, Independent) Director for a 5-year term, pending shareholder approval. Mr. Sharma brings over 33 years of extensive experience in the pharmaceutical industry, having worked with leading healthcare organizations....
Kwality Pharmaceuticals has announced significant changes to its Board of Directors. Mr. Vinod Kumar Sharma has been appointed as an Additional Non-Executive Independent Director for five years, pending shareholder approval. Mr. Sharma brings over 33 years of extensive experience in the pharmaceutical industry, which is valuable for strategic growth and...
Kwality Pharmaceuticals has confirmed its compliance with SEBI regulations regarding the handling of dematerialized shares for the quarter ended June 30, 2025. The company's Registrar and Share Transfer Agent, Bigshare Services, verified that all securities received for dematerialization were processed, confirmed to depositories, and listed. Physical share certificates were cancelled,...
Kwality Pharmaceuticals has announced a board meeting to discuss the financial results for the quarter and half-year. The company highlighted its leadership in complex injectables manufacturing, with a diverse product range including sterile powders, injectables, tablets, and biologics from its multiple state-of-the-art facilities. Backed by 40+ years of experience, Kwality...
Kwality Pharmaceuticals has announced a delay in filing its Annual Secretarial Compliance Report for the year ended March 31, 2024, resulting in a Rs. 2,360 penalty, which has been paid. The company also faced a two-day delay in submitting the annual report for FY2024, triggering a Rs. 4,720 penalty, paid...
